Medicon Valley Alliance member Envigo are proud to announce the first in a series of symposia focussing on preclinical development. The first in this series are run in collaboration with our partner Lundbeck who will host this free symposium on Carcinogenicity studies.
A panel of industry experts will cover key aspects and considerations to have when performing these studies. Case studies and experiences with regulatory authorities will also be shared. We are sure this free afternoon event starting with a light lunch will be both educational and insightful.
Date: Thursday May 19th, 2016
Time: 13:00 – 17:00
Venue: Lundbeck Pharma A/S, Ottiliavej 9, 2500 Valby, Denmark
Register today to secure your free place
Speakers and topics:
Allan Dahl Rasmussen, ERT, DABT – Director, Head of Regulatory Toxicology and Safety Assessment
– H. Lundbeck A/S
Case story: The Carcinogenicity Assessment Document and how it is handled at Lundbeck
Alan Broadmeadow – Senior Toxicologics – Envigo
Requirement and design carcinogenicity studies – as well as termination of studies depending on mortality
Ian Taylor – Associate Director, Global Pathology – Envigo
Interpretation of pathology data in carcinogenicity studies – incorporating a discussion on the utility of historical control data
Jørgen Schützsack, DVM, ERT, DABT – Associate Director, Toxicology – LEO Pharma
Case story: Positive findings – relevance and regulatory implications
Gitte Frausing, Toxicologist and Principal Consultant – Data Standards Decisions
Electronic requirements for carcinogenicity studies
Gareth Thomas, Global Head of Statistics and Data Management – Envigo
Where are Envigo with SEND
Mark A. Mills, Vice President, Envigo
Importance of animal models chosen in carcinogenicity studies
